Global Expansion Growing interest from global distributors and regional partners (Taiwan PAHSCO, Gloryway in China, Medtechnica in Israel) alongside historical distribution deals with European partners suggests strong sales opportunities through regional OEM partnerships and channel expansion to accelerate ICU adoption of Clarity RMS.

Hospital Cost Savings Clarity RMS addresses ICU-acquired AKI, which incurs lengthy stays and high costs. Position opportunities around hospital cost containment and length-of-stay reductions to hospital finance committees and procurement by highlighting potential clinical and economic benefits.

Early Adoption First-of-its-kind continuous urine flow monitoring enables real-time renal assessment. Target early-adopter ICUs and tertiary centers with high AKI incidence to establish reference sites and accelerate wider clinical adoption.

Key Collaborations Existing partnerships with major distributors and a strategic OEM approach (Fresenius distribution in Europe previously) indicate a sales model that leverages established networks. Focus on scaling with distributors who already serve critical care and nephrology markets.

Small Team, High Impact RenalSense operates with a lean team but has secured notable funding and multiple international distribution agreements. Emphasize scalable sales plays, partner-led deployments, and rapid onboarding to convert pilot sites into recurring revenue.